Last reviewed · How we verify
NCT03221140
Outpatient Parenteral Antimicrobial Therapy (OPAT)
trial testing Outpatient parenteral antimicrobial therapy in Infections in 2,000 participants. Status unknown.
31 December 2025
Quick facts
| Lead sponsor | University of Lausanne Hospitals |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 2,000 |
| Start date | 1 January 2014 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across Switzerland |
Drugs / interventions tested
- Outpatient parenteral antimicrobial therapy — full drug profile →
Conditions studied
- Infections — all drugs for Infections →
Sponsor
University of Lausanne Hospitals
Who can join
18 and older, any sex, with Infections. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Outpatient parenteral antimicrobial therapy (OPAT) has been recognised as a useful, cost-effective and safe alternative to inpatient treatment, but no formal OPAT unit existed in Switzerland until recently. In December 2013 an OPAT unit was established at Lausanne University Hospital. The investigators plan to investigate the efficacy, safety and economicity of outpatient parenteral antimicrobial therapy administered at the new OPAT unit of the Lausanne University Hospital starting in January 2014 until December 2020.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Efficacy and safety of continuous infusions with elastomeric pumps for outpatient parenteral antimicrobial therapy (OPAT): an observational study.
Voumard R, Gardiol C, André P, Arensdorff L, et al · · 2018 · cited 43× · PMID 29982449 · DOI 10.1093/jac/dky224
Verify or expand the search:
- PubMed search for NCT03221140
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Infections
Currently open trials in the same condition.
- NCT07512141 — Single Versus Double Drains in the Axillary and Pectoral Regions After Modified Radical Mastectomy · NA · recruiting
- NCT07189858 — Light-Activated Antimicrobial Therapy to Prevent Surgical Site Infections - Canada · NA · active not recruiting
- NCT06426147 — L-citrulline to Improve Adverse Outcomes in Admitted Children (EChiLiBRiST, Clinical Trial 2, Inpatients) · NA · recruiting
- NCT06911658 — Infectious Complications After Esophagectomy · recruiting
- NCT06145724 — EnCoRe MoMS: Engaging Communities to Reduce Morbidity From Maternal Sepsis (Aim 1) · NA · recruiting
Other University of Lausanne Hospitals trials
Trials by the same sponsor.
- NCT06912906 — Feasibility Study to Compare Two Ventilatory Modes for Mechanical Ventilation Weaning · NA · not yet recruiting
- NCT06482489 — Accurate Prostate Cancer Following Using Low-Field MRI (Low-PRISM) · recruiting
- NCT06552832 — CAVEAT: An Open-Trial Feasibility Study · NA · recruiting
- NCT05927324 — Clinician-Assisted Videofeedback Exposure-Approach Therapy (CAVEAT) Trial · NA · recruiting
- NCT06320457 — A Brief Case Management Intervention for People Involuntarily Admitted to a Psychiatric Hospital · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03221140 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Lausanne Hospitals
- Last refreshed: 15 December 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03221140.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing